shr 6390

Dalpiciclib (SHR-6390) is a highly selective, orally bioavailable, and comparable potency inhibitor of CDK4 and CKD6 with IC50s of 12.4 nM and 9.9 nM, respectively. Dalpiciclib exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated tumor suppressor retinoblastoma protein (Rb) and inducing G1 cell cycle arrest.

Dalpiciclib (isethionate) is a CDK4/6 inhibitor that suppresses the kinase activity of CDK4 and CDK6, thereby blocking the cell cycle transition from the G1 phase to the S phase, which inhibits abnormal cell proliferation. Dalpiciclib (isethionate) is utilized in breast cancer research.

Dalpiciclib (SHR-6390) hydrochloride is a highly selective, orally active CDK4/6 inhibitor with IC50 values of 12.4 nM and 9.9 nM, respectively, acting as an antitumor agent in breast and esophageal squamous cell carcinomas.